NCT02304354View on ClinicalTrials.gov

Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 9, 2015

Primary Completion Date

April 9, 2019

Study Completion Date

December 18, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Rituximab

For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.

Trial Locations (8)

29609

Rhumatologie, CHRU de BREST, Brest

37044

Rhumatologie, CHRU de TOURS, Tours

44093

Rhumatologie, CHRU de NANTES, Nantes

45000

Rhumatologie / IPROS, CHR d'ORLEANS, Orléans

72037

Rhumatologie, CHR du MANS, Le Mans

76031

Rhumatologie, CHRU de ROUEN, Rouen

85925

Rhumatologie, CHD LA ROCHE SUR YON, La Roche-sur-Yon

86021

Rhumatologie, CHRU de POITIERS, Poitiers

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT02304354 - Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX) | Biotech Hunter | Biotech Hunter